Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth quarter. The cut, which William Blair analysts called a “shocking ...

Exact Sciences (NASDAQ:EXAS) has filed a lawsuit in federal court alleging that Geneoscopy’s ColoSense product infringes upon a key patent for its colorectal cancer screening test Cologuard.

Exact Sciences rose Friday after the Food and Drug Administration approved its next-generation colon cancer detection test, ...

In the latest quarter, 7 analysts provided ratings for Exact Sciences (NASDAQ:EXAS), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

She previously served as the senior associate dean for research in the College of Communication Arts and Sciences and professor in the Department of Communication and AgBioResearch at Michigan State ...

Chris Russo stopped himself at first before deciding to go for it. Russo has poured cold water on the idea that the public cares as much as the sports media does about Bronny James taking the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...